📊 VCEL Key Takeaways
Is Vericel Corp (VCEL) a Good Investment?
Vericel maintains a fortress balance sheet with exceptional liquidity ($109.3M cash, 5.18x current ratio) and generates positive free cash flow ($15.1M) despite operating losses, supported by industry-leading 72% gross margins. However, stagnant revenue growth (0% YoY) combined with persistent operating losses (-11.8% margin) create fundamental concerns about the company's ability to reach sustained profitability without demonstrating top-line acceleration.
Vericel Corp Key Strengths (VCEL)
- Exceptional gross margin of 72% indicates strong pricing power and efficient manufacturing in biological products
- Fortress balance sheet with $109.3M cash, minimal debt ($13.2M), and 0.04x debt/equity ratio provides substantial financial cushion
- Positive operating and free cash flow ($16.4M and $15.1M respectively) despite net losses, suggesting improving underlying operational efficiency
- Significant profitability improvement trending positively (59.4% net income improvement, 60% EPS improvement YoY)
VCEL Stock Risks: Vericel Corp Investment Risks
- Zero revenue growth (0% YoY) indicates stagnant market presence and potential competitive or demand headwinds
- Persistent operating losses (-11.8% margin) and negative net margin (-9.2%) show core business remains unprofitable despite improvement trajectory
- Elevated insider activity (26 Form 4 filings in 90 days) warrants monitoring for potential strategic or capital allocation concerns
- Unclear path to sustainable profitability; without revenue growth, operating margin must improve significantly to reach breakeven and positive returns
Key Metrics to Watch
- Revenue growth acceleration - critical to validate business viability and market demand
- Operating margin progression toward positive territory - signals when core business becomes self-sustaining
- Gross margin stability - ensure 72% level is maintained amid potential pricing or cost pressures
- Operating cash flow sustainability - confirm positive cash generation continues during growth phase
Vericel Corp (VCEL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 22.1% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 5.18x current ratio provides a solid financial cushion.
VCEL Profit Margin, ROE & Profitability Analysis
VCEL vs Healthcare Sector: How Vericel Corp Compares
How Vericel Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vericel Corp Stock Overvalued? VCEL Valuation Analysis 2026
Based on fundamental analysis, Vericel Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vericel Corp Balance Sheet: VCEL Debt, Cash & Liquidity
VCEL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vericel Corp's revenue has grown significantly by 80% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.07 indicates the company is currently unprofitable.
VCEL Revenue Growth, EPS Growth & YoY Performance
VCEL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $52.6M | -$6.3M | $-0.12 |
| Q3 2025 | $57.9M | -$553.0K | $-0.02 |
| Q2 2025 | $52.7M | -$553.0K | $-0.01 |
| Q1 2025 | $51.3M | -$3.9M | $-0.08 |
| Q3 2024 | $45.6M | -$901.0K | $-0.02 |
| Q2 2024 | $45.9M | -$3.9M | $-0.10 |
| Q1 2024 | $41.0M | -$3.9M | $-0.08 |
| Q3 2023 | $38.3M | -$3.7M | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vericel Corp Dividends, Buybacks & Capital Allocation
VCEL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vericel Corp (CIK: 0000887359)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VCEL
What is the AI rating for VCEL?
Vericel Corp (VCEL) has an AI grade of B with 70% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VCEL's key strengths?
Claude: Exceptional gross margin of 72% indicates strong pricing power and efficient manufacturing in biological products. Fortress balance sheet with $109.3M cash, minimal debt ($13.2M), and 0.04x debt/equity ratio provides substantial financial cushion.
What are the risks of investing in VCEL?
Claude: Zero revenue growth (0% YoY) indicates stagnant market presence and potential competitive or demand headwinds. Persistent operating losses (-11.8% margin) and negative net margin (-9.2%) show core business remains unprofitable despite improvement trajectory.
What is VCEL's revenue and growth?
Vericel Corp reported revenue of $68.4M.
Does VCEL pay dividends?
Vericel Corp does not currently pay dividends.
Where can I find VCEL SEC filings?
Official SEC filings for Vericel Corp (CIK: 0000887359) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VCEL's EPS?
Vericel Corp has a diluted EPS of $-0.12.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VCEL's fundamental grade?
Based on our AI fundamental analysis in June 2026, Vericel Corp has a B grade with 70% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VCEL stock overvalued or undervalued?
Valuation metrics for VCEL: ROE of -1.8% (sector avg: 15%), net margin of -9.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is VCEL's AI grade for 2026?
Our dual AI analysis gives Vericel Corp a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VCEL's free cash flow?
Vericel Corp's operating cash flow is $16.4M, with capital expenditures of $1.3M. FCF margin is 22.1%.
How does VCEL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9.2% (avg: 12%), ROE -1.8% (avg: 15%), current ratio 5.18 (avg: 2).